Navitas Systems (United States)

Recent papers from Navitas Systems (United States)

1. PD GENEration: an international Parkinson’s disease genetic research studyBMC Neurology · 2026
2. Perspectives on plasma biomarkers for point-of-care diagnostics in Alzheimer's disease: Insights into 2D-BioPADJournal of Alzheimer s Disease Reports · 2026
3. Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry DataAdvances in Therapy · 2026
4. TWEAK receptor (Fn14) exacerbates TNF-α-induced inflammation in rheumatoid arthritis synovial fibroblasts and influences response to anti-TNF-α therapyCellular and Molecular Immunology · 2026
5. Educational Resilience During the COVID-19 Pandemic: A Descriptive Evaluation of Medical School and Licensing Examination Policies in JapanCureus · 2025
6. Characterization of Second‐Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis RegistryACR Open Rheumatology · 2025
7. Hemoglobin-Based Oxygen Carriers: Selected Advances and Challenges in the Design of Safe Oxygen Therapeutics (A Focused Review)International Journal of Molecular Sciences · 2025
8. OxyVita®C Hemoglobin-Based Oxygen Carrier Improves Viability and Reduces Tubular Necrosis in Ex Vivo Preserved Rabbit KidneysInternational Journal of Molecular Sciences · 2025
9. Development and External Validation of a Multivariable Predictive Model for Progression to Difficult‐to‐Treat Rheumatoid Arthritis in Biologic‐Experienced PatientsArthritis Care & Research · 2025
10. Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis RegistryJEADV Clinical Practice · 2025
11. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council ClassificationDermatology and Therapy · 2025
12. US FDA–accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelinesInvestigational New Drugs · 2025
13. Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injectorDermatology and Therapy · 2025
14. Association of opioid and benzodiazepine coprescribing with adverse events among older adults with cancerJNCI Journal of the National Cancer Institute · 2025
15. Impact of Fatigue on Work Productivity, Activity Impairment, and Healthcare Resource Utilization in Inflammatory Bowel DiseaseCrohn s & Colitis 360 · 2024
16. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis RegistryClinical Rheumatology · 2024
17. Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North AmericaJournal of Psoriasis and Psoriatic Arthritis · 2024
18. The Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic TherapyPsoriasis Targets and Therapy · 2024
19. Three-Year Clinical Outcomes in Geographic AtrophyRetina · 2024
20. Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipinsRMD Open · 2024